(Q42954068)

English

Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?

scientific article published on November 15, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

0 references

invasive aspergillosis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Christelle Kassis

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Ying Jiang

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Coralia N. Mihu

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20665889

12 June 2024

Elizabeth R. Ramos

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20665889

12 June 2024

Ray Y. Hachem

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20665889

12 June 2024

Issam I. Raad

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20665889

12 June 2024

language of work or name

0 references

publication date

1 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

15 November 2010

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20665889

12 June 2024

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.25312

1 reference

10.1002/CNCR.25312

https://api.crossref.org/works/10.1002/CNCR.25312

12 June 2024

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25312/fullpdf

1 reference

10.1002/CNCR.25312

https://api.crossref.org/works/10.1002/CNCR.25312

12 June 2024

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

5290-5296

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Fungal infections in cancer patients: an international autopsy survey.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

Echinocandins and pneumocandins--a new antifungal class with a novel mode of action

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

21 January 2018

Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

7 January 2021

based on heuristic

inferred from DOI database lookup

Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of therapeutic early onset granulocyte transfusions in pediatric patients with neutropenia and severe infections

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25312

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25312

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42954068&oldid=2177012899"